Sanofi's Dengvaxia Postmarket Monitoring Plan Targets Vaccine's Safety Concerns

Company proposes enhanced real-world monitoring to identify dengue vaccine’s risks, including severe and hospitalized dengue in individuals not previously infected, US FDA says in briefing document for March 7 advisory committee meeting.